Key Takeaways
- 77% YoY revenue growth, CDMO-led: CDMO surged 113% YoY, driving a 305% EBITDA jump and a swing to PAT of ₹60 crores from a loss a year ago.
- Margins leap on operating leverage: EBITDA margin expanded sharply as scale efficiencies and productivity gains flowed through; management sees a path to 28–30% margins as revenues grow.
- Phase III pipeline churn is normal, not alarming: Two molecules commercialized, two failed in the clinic, netting to 6 active Phase III programs. The failures are attributed to trial design, not molecule quality.
- China-plus-one tailwind is structural and accelerating: IP concerns in China are pushing customers toward Indian CDMOs, and Sai’s early investments in high-end science and manufacturing position it to capture that shift.
- What to watch next quarter: Whether the 30% expansion with a dedicated CRO client flows through immediately as guided, the pace of biotech funding recovery for early discovery, and any updates on the two positive Phase III readouts.
CDMO Performance & Drivers
- Broad-based growth, not one-off: The 113% YoY CDMO jump came from existing commercial molecules scaling up and new products entering commercial stage, with no launch-related stocking or one-time revenue.
- Phase III pipeline movement: Two molecules moved into commercialization, two dropped out due to clinical trial failure. Management does not know the exact reasons for the failures, citing possible patient selection or clinical endpoint decisions.
- New modalities nearing commercial reality: Oligonucleotides are close to commercial, ADCs have a late-phase asset that is effectively commercial, while peptides remain early in the clinic. Lipids have been supplied for 7–8 years.
- Two positive Phase III readouts: A couple of months ago, two Phase III molecules delivered positive data, and one small molecule just received approval, though management flagged it is not a very large revenue contributor.
Krishna Kanumuri: "I would say right now, at least visibility is strong at this point. I don't know if it's always going to be the case, but this investment is based on a better visibility than we had done in the past."
CRO Business & Discovery
- Integrated Discovery programs anchor growth: The CRO business continues to expand on the back of large, integrated programs rather than fragmented standalone contracts.
- Dedicated CRO client expansion: A 30% expansion in business with one dedicated CRO client was secured a month and a half ago, and management expects the benefit to flow through immediately from Q2.
- Biology facility deepens the moat: The newly launched biology facility in Hyderabad enhances Sai’s ability to support complex targets and strengthens its role in large integrated programs, making it harder for clients to unbundle the relationship.
- Discovery space growing 30%: Additional discovery capacity is on track to come online by the end of the fiscal year, signaling confidence in the forward pipeline.
China-Plus-One & Competitive Positioning
- China is still ahead, and that is the opportunity: Management candidly stated that China remains significantly ahead of India in both scale and technology on an apples-to-apples basis, meaning the diversification runway is long.
- IP concerns are the real driver: The issue moving customers away from China is not cost but intellectual property, as Chinese CDMOs have become competitors to their pharma clients on the discovery side.
- Early investments created the right to win: Sai invested in 2018–19 to become a science-driven, high-end manufacturing and discovery company, and that forward-looking approach is what management credits for current business wins.
- Big Pharma building for the long run: Large pharma companies are building their India footprint with a long-term view, and management expects more traction from Big Pharma in the immediate term.
Krishna Kanumuri: "The one issue which has come up in China, which is actually moving customers away, is IP issues have come up in China, primarily because China has become a competitor for them on the Discovery side."
Capacity Expansion & Capex
- Manufacturing capacity up 80% by 2027: Two new production blocks totaling 450 KL will come online, with the first 200 KL block arriving by Q3 FY27 and the second toward the end of FY27, against a base of 1,200–1,300 KL.
- Process R&D doubling by next year: A new Process R&D block will nearly double current capabilities and add clinical-scale peptide and early-phase formulation capabilities.
- ₹700 cr capex this year: Management committed to ₹700 cr for the current year and indicated there will be capex next year as well, though no number was given.
- Bridge plan for capacity shortages: Until new capacity comes online, Sai has plans to use external agencies to ride through any shortages.
- Utilization at 77% with nuance: The 100 KL commissioned at the end of Q1 was not fully utilized, and utilization depends on the mix of commercial versus development projects.
Demand Environment & Biotech Funding
- RFQ/RFP flow is healthy: Management characterized the incoming request flow as pretty healthy, supporting the capacity investment thesis.
- Biotech funding is back, but smaller: Biotech funding has returned, but it is concentrated on later-stage assets benefiting the CDMO side. Discovery funding is coming back at lower investment levels, with biotechs returning with 20–30 FTE programs rather than the 100–150 FTE programs seen earlier.
- H2 expected to be better than H1: Management confirmed the general trend of H2 outperforming H1 should continue, though it declined to give specific guidance or split the trend by CRO versus CDMO.
- US reshoring not yet a threat: On paper, US reshoring policy does not appear to have impacted Sai, though management acknowledged the situation could shift.
Margins & Profitability
- Operating leverage drove the 305% EBITDA jump: Margin expansion came from scale efficiencies and improved productivity across sites, not from any one-off items. Management confirmed no one-offs were accounted in Q1.
- 28–30% margin target as revenues scale: Management stated the business can be scaled to achieve 28–30% margins, and Q1 results show positive movement toward that goal.
- CRO carries a margin premium: On a steady-state basis, the CRO side will have a few basis points more margin than the CDMO side, though management declined to provide the split.
- Asset turns tracked internally: Management uses an internal metric of 1.2 to 1.4x on a net basis, providing a lens on capital efficiency as capacity comes online.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 15% average growth rate | 3–5 year horizon |
| Manufacturing capacity | 80% increase from 1,200–1,300 KL base | By 2027 |
| First new production block | 200 KL online | Q3 FY27 |
| Second new production block | Additional 250 KL online | End of FY27 |
| Process R&D capacity | Nearly double current | By next year |
| Discovery space | 30% additional space | End of current fiscal year |
| Capex (current year) | ₹700 cr | FY26 |
| CRO client expansion benefit | 30% expansion flows through | Immediately from Q2 |
| EBITDA margin target | 28–30% | As revenues grow (no date) |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Revenue | ₹496 cr, +77% YoY vs ₹218 cr in Q1 FY25 |
| CDMO revenue | ₹314 cr, +113% YoY vs ₹148 cr in Q1 FY25 |
| CRO revenue | ₹182 cr, +38% YoY vs ₹132 cr in Q1 FY25 |
| EBITDA | ₹125 cr, +305% YoY vs ₹31 cr in Q1 FY25 |
| EBITDA margin | 25%, +14 ppt YoY improvement |
| PAT | ₹60 cr, vs loss of ₹13 cr in Q1 FY25 |
| Capex | ₹134 cr in Q1; full-year FY26 plan of ₹700 cr |
| CDMO capacity utilization | ~77% at end of Q1; 70-75% considered decently fully utilized |
| CDMO capacity added | 100 KL commissioned at end of Q1 |
| CDMO capacity base | ~600 KL at end of FY25; 550 KL addition planned, taking total to ~1,150 KL by H2 FY27 |
| Phase III pipeline | 6 molecules, down from 10; 2 moved to commercial, 2 dropped out due to clinical trial failure |
| Scientists onboarded | 250+ during the quarter |
| Client and regulatory audits | 11 completed across sites during the quarter |
| Top 10 customer concentration | ~40% of revenue, reported on a full-year basis |
| CRO customer split | 38% Big Pharma, 62% Biotech |